Founded in April 2019, JunRui Biotechnology focuses on the discovery, development and commercialization of antineoplastic drugs through collaboration with both academy and industry. In particular, Junrui Biotechnology has developed a series of novel small molecule anti-cancer agents based on CXCR4/CXCL12 signal axis.
In the future, under the leadership of co-founders, JunRui Biotechnology will continue to research and develop first-in-class or best-in-class anti-cancer drugs, enriching the company's R&D pipeline and exploring novel therapies in oncology and related fields, to meet the unmet medical need for patients in China and around the globe.
